Capital Impact Advisors’s iRadimed IRMD Stock Holding History

Capital Impact Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-17,619	Closed	-$841K	–	142
2023 Q2	$841K	Sell	17,619 -1,771	-9%	-$79.9K	0.93%	22
2023 Q1	$763K	Sell	19,390 -980	-5%	-$35.6K	0.94%	28
2022 Q4	$576K	Hold	20,370	–	–	0.56%	63
2022 Q3	$575K	Buy	20,370 +1,214	+6%	+$42.3K	0.57%	58
2022 Q2	$650K	Sell	19,156 -3,641	-16%	-$131K	0.6%	58
2022 Q1	$1.02M	Buy	22,797 +8,536	+60%	+$395K	0.74%	34
2021 Q4	$659K	Buy	+14,261	New	+$575K	0.45%	67

Other funds holding IRMD

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMC

RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return

BCM

Bares Capital Management Austin, Texas $1.08B AUM 38.13% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Capital Impact Advisors's IRMD Position: Q3 2023 in Review

Capital Impact Advisors sold out of iRadimed (IRMD) in Q3 2023, closing a stake of 17,619 shares — an estimated $841K sold.

Capital Impact Advisors first reported a position in IRMD in Q4 2021 and held it in 7 quarters. The position peaked at $1.02M in Q1 2022. 113 funds tracked by Wall St. Rank hold IRMD as of Q3 2023.

Capital Impact Advisors reported no remaining iRadimed position as of Q3 2023 after selling out during the quarter.
Capital Impact Advisors sold 17,619 iRadimed shares in Q3 2023, an estimated $841K.
Capital Impact Advisors first reported a position in iRadimed in Q4 2021 and held it in 7 quarters.
Capital Impact Advisors's iRadimed position peaked at $1.02M in Q1 2022.
113 funds tracked by Wall St. Rank held iRadimed as of Q3 2023.

Based on Capital Impact Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.